Drugs / Sacubitril/valsartan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06142383 Comparator | Dec 2023 → Nov 2024 | heart failure | Novartis Pharmaceuticals | Terminated | Missed primary Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06142383 ↗ |
| Known as | Sac/Val | “Sacubitril/valsartan, open label tablet, 97/103 mg bid (Sac/Val)” NCT06142383 ↗ |